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Abstract
Purpose: Taking full advantage of positron emission tomography (PET) technology, fluorine-18-
labelled radiotracers targeting norepinephrine transporter (NET) have potential applications in
the diagnosis and assessment of cardiac sympathetic nerve conditions as well as the
delineation of neuroendocrine tumours. However, to date, none have been used clinically.
Drawbacks of currently reported radiotracers include suboptimal kinetics and challenging
radiolabelling procedures.
Procedures: We developed a novel fluorine-18-labelled radiotracer targeting NET, AF78, with
efficient one-step radiolabelling based on the phenethylguanidine structure. Radiosynthesis of
AF78 was undertaken, followed by validation in cell uptake studies, autoradiography, and in vivo
imaging in rats.
Results: [18F]AF78 was successfully synthesized with 27.9 ± 3.1 % radiochemical yield, 9 97 %
radiochemical purity and 9 53.8 GBq/mmol molar activity. Cell uptake studies demonstrated
essentially identical affinity for NET as norepinephrine and meta-iodobenzylgaunidine. Both
ex vivo autoradiography and in vivo imaging in rats showed homogeneous and specific cardiac
uptake.
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Conclusions: The new PET radiotracer [18F]AF78 demonstrated high affinity for NET and
favourable biodistribution in rats. A structure-activity relationship between radiotracer structures
and affinity for NET was revealed, which may serve as the basis for the further design of NET
targeting radiotracers with favourable features.
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Introduction
In recent years, the development of positron emission
tomography (PET) technology has increasingly been ex-
plored for cardiac and other applications due to its higher
spatial and temporal resolution compared to single photon
emission computed tomography (SPECT) [1]. This allows
for a broader range of potential functional and kinetic
analyses [2]. Fluorine-18-labelled radiotracers (physical
half-life, 110 min) maximize the potential applicability of
PET compared to carbon-11-labelled radiotracers (physical
half-life, 20 min). As a result of the longer half-life and other
intrinsic advantages, fluorine-18-labelled agents (1) obviate
the need for on-site cyclotrons and allow central distribution
of radiotracers; (2) facilitate performing a large number of
scans each day; and (3) allow flexible radiotracer design and
possible improvement of stability against metabolism [3].
To date, a handful of fluorine-18-labelled PET radio-
tracers have been reported that target norepinephrine
transporter (NET). The interest in NET is because it is not
only a major diagnostic focus in cardiovascular diseases [4–
6] but also a therapeutic target in neuroendocrine tumours
[7]. Typical examples include (1) 6-[18F]fluorodopamine,
which was first reported more than 20 years ago [8, 9]; (2)
[18F]meta-fluorobenzylguanidine ([18F]MFBG), which is the
fluoride analogue of the only clinically used NET radiotracer
[123I]meta-iodobenzylguanidine ([123I]MIBG), a single-
photon emitting compound [10, 11]; (3) 1-(3-bromo-4-(3-
[18F]fluoropropoxy)benzyl)guanidine ([18F]LMI1195),
which shares comparable in vitro and in vivo characteristics
as [123I]MIBG due to a common benzylguanidine core
s t r u c t u r e [ 1 2–14 ] ; a n d ( 4 ) 4 - [ 1 8 F ] f l u o r o - 3 -
hydroxyphenethylguanidine ([18F]4F-MHPG) and its isomer
3-[18F]fluoro-4-hydroxyphenethylguanidine ([18F]3F-
PHPG), which have shown unique slow uptake kinetics
due to their phenethylguanidine core structures [15, 16]
(Fig. 1). Among these radiotracers, [18F]LMI1195 [17] and
[18F]4F-MHPG/3F-PHPG [18, 19] have been used mainly
for cardiac sympathetic innervation imaging and have shown
acceptable safety and favourable properties in clinical phase
1 trials.
As of now, there is no PET radiotracer that has been
approved by a regulatory body for clinical use, because all
the fluorine-18-labelled radiotracers mentioned above still
hold some drawbacks: First, the high cardiac extraction of
easily labelling [18F]LMI1195 is a limitation for kinetic
analysis, since its uptake is consequently blood flow
dependent. Second, [18F]4F-MHPG/3F-PHPG shows slow
uptake that enables prospective quantitative analysis, but
poor radiolabelling yields due to the nature of
radiofluorination on electron-rich benzene ring hinders their
broader application. In order to provide clinicians more
choices and to investigate the relationships between the
structures of radiotracers and affinity for NET, we propose
two new fluorine-18-labelled compounds, AF51 and AF78.
They also represent phenethylguanidine core structure of
[18F]4F-MHPG and [18F]3F-PHPG, respectively, yet with 3-
fluoropropoxy substitution (Fig. 2)—a strategy to develop
[18F]LMI1195 from [123I]MIBG. Thus, a new series of NET
targeting fluorine-18-labelled PET radiotracers with advan-
tageous characteristics are designed: They bear the
pharmacophore that is required for slow uptake kinetics
along with simple radiofluorination moiety that would be
more suitable for potential clinical application with higher
radiochemical yield. It is noteworthy that such compounds
are not a simple combination of chemical structures but
might also reveal the pattern of substitution tolerability and
provide new insights into radiotracer design.
Materials and Methods
General
Solvents were dried according to published methods and
freshly distilled before use. All other reagents were
commercially available compounds and were used without
further purification unless noted otherwise. All reactions
were carried out under a nitrogen atmosphere. H-1 and C-13
NMR spectral data were obtained from a Bruker Avance II
400 MHz NMR scanner. H-1 and C-13 NMR chemical
shifts (δ) are reported in parts per million (ppm) relative to
internal standard TMS, and coupling constants (J) are in
hertz. Thin layer chromatography was performed on silica
gel 60 with a 254-nm fluorescent indicator. UV light or
iodine vapour were used for detection. Purity was evaluated
on an LCMS system by Shimadzu Products, containing a
LC20AB liquid chromatograph, an SPD-20A UV/Vis
detector and a DGU-20A3R degassing unit. Stationary phase
was a Synergi 4 μm fusion-RP (150 × 4.6 mm) column
(Phenomenex, Aschaffenburg, Germany). Mass spectra were
obtained by a Shimadzu LCMS-2020 (confirming purity ≥
95 %). For column chromatography, silica gel 60, 230–400
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mesh by Merck was used. For preparative thin layer
chromatography, silica gel 60 PF254 by Merck was used.
Radiochemistry
[18F]Fluoride trapped on a Sep-Pak QMA cartridge was first
washed with distilled water (3 ml) to remove [18O]water.
[18F]Fluoride was then eluted from the cartridge with K2CO3
solution (0.3 ml, 23 μmol/ml) into a vial that contained
Kryptofix222 (22.5 mg, 59.7 μmol). Acetonitrile (4 × 0.5 ml)
was added to the vial, and the solution was dried
azeotropically under argon at 120 °C. Labelling was carried
out by adding the solution of the precursor (4.8 mg) in dry
acetonitrile (0.3 ml), followed by heating and stirring at
110 °C for 10 min. Hydrochloric acid (6 N, 0.3 ml) was
added to the reaction mixture, and the reaction continued for
20 min at 100 °C. The mixture was cooled, diluted with 1 ml
of a mixture solution of water and acetonitrile (1:1), and
applied to the semi-preparative HPLC for purification.
HPLC conditions were as follows: column 9.4 × 250 mm
5-μm ZORBAX Eclipse XDB-C18 (P.N. 990967-202).
Mobile phase: Phase A: Millipore water with 0.1 % formic
acid; Phase B: Methanol with 0.1 % formic acid. Condition:
0–20 min, 30–60 % B, 20–22 min 60–100 % B, 22–50 min
100 % B; Flow rate 3 ml/min. Condition of autoradiography:
TLC with normal phase silica gel 60. Solvent system: 3 ml
methanol + 20 μl formic acid, Rf.: 0.6.
Competitive Cell Uptake Studies
SK-N-SH cells expressing NET were cultivated according
to the instructions from the supplier (Sigma-Aldrich Chemie
GmbH, Munich, Germany). The cells were transferred to a
12 well plate and incubated in 1 ml Eagle’s minimum
essential medium (EMEM) while reaching 2 × 105 cells/
well density on the day for testing. The medium was
removed, and the cells were washed with 1 ml EMEM. A
solution of [131I]MIBG (Freiburg im Breigau, Germany) or
[18F]AF78 (3.7 kBq) in EMEM (700 μl) was added to each
well together with the testing compounds (norepinephrine,
4F-MHPG and cold reference AF78, each to a final
concentration 100 nM, 1 μM, 10 μM and 100 μM,
respectively) with or without the inhibitor desipramine
(10 μM). The plate was incubated for 60 min at 37 °C.
The cells were washed with ice-cold PBS buffer (2 × 1 ml)
in order to remove unbound radiotracer. NaOH solution
(0.1 N, 500 μl) was added to each well followed by the
collection of cell pellet and measurement in a γ-counter
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Fig. 1 Chemical structures of the neurotransmitter norepinephrine and selected radiotracers derived from it.
Fig. 2 The strategy to develop new fluorine-18-labelled PET tracers targeting sympathetic nerve system along with proposed
structures of target tracers.
(FH412, Frieseke & Höpfner, Erlangen, Germany) using
differential energy windows (± 20 %) for fluorine-18 and
iodine-131.
Ex vivo Autoradiography and Tissue Counting
Studies
Standard protocols and data analysis methods for non-
invasive PET imaging of small animals have been
established in our group [20]. Healthy male Wistar rats
(Japan SLC, Inc., Shizuoka, Japan) each weighing 200–
250 g were utilized. The rats were anaesthetized with 2 %
isoflurane. Ten to 20 MBq of [18F]AF78 were administered
via tail vein injection. Ten minutes after radiotracer
administration, the animals were euthanized. Hearts, livers
and blood were obtained for ex vivo analysis with
autoradiography (Typhoon FLA 7000) and tissue counts
with a γ-counter (1480 WIZARD™ 3″). Following weight
and decay correction of tissue counts, the heart-to-blood
(H/B) and heart-to-liver (H/L) count ratios were calculated.
For autoradiography, the rats under anaesthesia were first
injected via tail vein either with or without the NET
blocker phenoxybenzamine (50 mg/kg). After 10 min, the
radiotracer (10–20 MBq) was administered. The hearts
were harvested 10 min later, frozen, and cut into 20 μm
short axis slices using a cryostat (Cryotome FSE, Thermo
Fisher Scientific), which were then immediately exposed to
the autoradiography plates (Fuji SR-type image plate,
Fujifilm Corporation, Tokyo, Japan) for 18 h to obtain
the radiotracer distribution. The images were obtained
using a digital autoradiographic system (Typhoon FLA
7000).
Cardiac PET Imaging in Animals
Anaesthesia was induced in male Wistar rats by using 5 %
isofluorane and was maintained during the whole experi-
ment with 2 % isoflurane. All scans were obtained using a
dedicated small-animal PET system (microPET FOCUS
120, SIEMENS, Munich, Germany). The PET imaging
protocol was designed to assess the systemic and myocar-
dial radiotracer distribution of [18F]AF78. Shortly before
the injection of [18F]AF78 (10–20 MBq) via the tail vein, a
10 min dynamic PET scan was initiated with the acquisition
in list-mode format. In order to evaluate the cardiac uptake
mechanism of the radiotracer, rats were pretreated with
phenoxybenzamine (50 mg/kg intravenously, Sigma-Al-
drich, Tokyo, Japan) 10 min before radiotracer injection
(10–20 MBq). The data were sorted into 3-dimensional
sinograms, which were then reconstructed with a Fourier
transform to produce dynamic images using a 2-
dimensional ordered-subset expectation maximization
(OSEM) algorithm. All images were corrected for
fluorine-18 decay, random and dead time; correction for
attenuation was not performed [12]. The obtained PET
images were analysed with the public domain tool AMIDE
imaging software (A Medical Imaging Data Examiner,
version 1.01).
Statistical Analysis
All results are displayed as mean ± SD. The two-tailed
paired Student’s t test was used to compare differences
between two dependent groups, and the two-tailed indepen-
dent Student’s t test for differences between independent
groups. A p value of less than 0.05 was assumed to be
statistically significant. Statistical analysis was performed
with StatMate III (ATMS Co., Ltd., Tokyo, Japan).
Results
Synthesis
For details regarding radiotracer synthesis and approaches as
well as mechanism discussions, please refer to Electronic
Supplementary Material (ESM). In short, in order to
determine affinity to NET and to serve as references for
the labelled compound, cold references (nonradioactive
fluorine-19 compounds) of the target radiotracers AF51
and AF78 (Fig. 2) were first synthesized based on the
reported approaches with similar structures [16, 21] (Figs.
S1–S3, c.f. ESM). After the evaluation in cell uptake studies
as compared to norepinephrine and MIBG, AF78 retains the
same affinity as its lead compound and showed almost equal
affinity to norepinephrine, whereas AF51 lost NET affinity
(Fig. 4). Consequently, only the precursor of AF78 was
pursued further.
As learned from the preparation of [18F]MFBG [22, 23],
a fully protected guanidine moiety 5 (Fig. S4, c.f. ESM) was
utilized to introduce this moiety to the precursor in order to
improve its stability during the radiofluorination procedure
and thereby facilitating a higher labelling yield. Moreover,
by using a Wittig reaction followed by a one-pot
oxymercuration and reduction elimination reaction [24, 25],
the synthetic procedure to generate the phenethylene moiety
4 was shortened to two steps (Fig. 3) as compared to the
cold references (Figs. S2 and S3 c.f. ESM). After the
Mitsunobu reaction between the phenylethanol 4 and fully
protected guanidine moiety 5, tosylate was introduced as a
leaving group for the radiofluorination (Fig. 3).
Radiochemistry
Radiolabelling was performed in a one-pot, two-step
reaction procedure, with the nucleophilic radiofluorination
followed by deprotection of the fully protected guanidine
moiety under acidic conditions. In the initial plan, the
second step was done using 0.3 ml of 1 N HCl. However,
after doubling the amount and concentration of acid with
either longer heating time (10, 20, 30 min) or different
Chen X. et al.: Novel NET tracer [18F]AF78 605
reaction temperature (room temperature 40 °C, 70 °C), one
unidentified polar peak on HPLC with significant quantity
after integration did not change (Figs. S6 and S7, c.f. ESM).
After several investigations on TLC-autoradiography and
cold labelling attempts, the peak was eventually identified
as the deprotected intermediate, i.e., after the removal of
both Boc groups yet still with the triazinanone structure on
the guanidine (Fig. 3). This structure was more stable than
expected. Therefore, 6 N HCl was used for decomposition
of this moiety (Fig. S8, c.f. ESM). We consider this to be a
noticeable finding, which confirmed the stability of the fully
protected guanidine moiety and might be useful for
labelling of other radiotracers with similar structure under
relatively harsh reaction conditions. In addition to the small
problem of deprotection that has been encountered, the
overall radiolabelling procedure was straightforward and
could be finished manually within approximately 120 min.
The average radiochemical yield was 27.9 ± 3.1 % (decay-
corrected based on the starting radioactivity, n = 5) without
reaction condition optimization. The molar activity of the
target radiotracer was 9 53.8 GBq/mmol and the radio-
chemical purity 9 97 % confirmed by both TLC-
autoradiography (Fig. S9, c.f. ESM) and analytical HPLC
(Fig. S10, c.f. ESM).
Competitive Cell Uptake Studies
After successful syntheses of both cold references AF51 and
AF78, they were examined in SK-N-SH cells expressing
NET against the uptake of either [131I]MIBG [26] or
[18F]AF78. Norepinephrine and cold MIBG were used as
controls. Cold reference AF78 was able to inhibit the cell
uptake of [131I]MIBG in a concentration-dependent manner
with an IC50 value of 2.57 ± 1.37 μM as compared to 1.38 ±
0.25 μM and 6.80 ± 0.73 μM for norepinephrine and 4F-
MHPG, respectively (Fig. 4a). In contrast, cold reference
AF51 was not able to significantly inhibit the uptake of
[131I]MIBG even at the highest concentration tested,
generating only 40 % of inhibition at 100 μM. After
successful radiolabelling, [18F]AF78 was also evaluated in
SK-N-SH cells [14]. Norepinephrine (black), 4F-MHPG
(blue) and cold reference AF78 (red) inhibited the uptake of
[18F]AF78 at IC50 values of 0.60 ± 0.27 μM, 0.85 ±
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Fig. 3 Synthetic scheme to obtain the precursor of AF78 along with the radiolabelling to generate [18F]AF78, which was
prepared from its precursor in a one-pot, two-step labelling procedure. A deprotected intermediate was formed when using a
lower concentration of HCl, which confirmed our presumption of the stability of the fully protected guanidine moiety.
0.63 μM, and 2.68 ± 0.83 μM, respectively (Fig. 4b). These
results are in accordance with the outcomes achieved above
while using [131I]MIBG as reference. Furthermore, the cell
uptake mechanism was confirmed by the addition of the
antidepressant drug desipramine (DMI), which can selec-
tively inhibit NET-mediated transportation. Ninety-four
percent of the uptake of [18F]AF78 was inhibited by DMI
as compared to 87 % of the uptake of [131I]MIBG (Fig. 4c).
Cardiac Imaging Studies in Rats
In the ex vivo autoradiography study [20], [18F]AF78
showed homogenous radiotracer uptake throughout the left
ventricular wall in healthy rats (Fig. 5a). A lack of
delineation of the right ventricular wall might be due to its
thinness and the slicing position. This accumulation was
significantly suppressed by pretreatment with the NET
blocker phenoxybenzamine (PhB, 50 mg/kg) 10 min before
radiotracer injection (Fig. 5a).
The tissue counting study revealed that the radiotracer
has selective uptake in the heart as demonstrated in both
heart-to-blood (H/B) and heart-to-liver (H/L) ratios (12.54
± 0.53 and 6.14 ± 0.35, respectively). This uptake was
specifically blocked by PhB (50 mg/kg) and led to
approximately 6-fold decline (≈ 81 %) in the H/B ratio
and 5-fold decline (≈ 79 %) in the H/L ratio (2.41 ± 0.58
and 1.30 ± 0.54, respectively) (Fig. 5b).
A small animal PET imaging protocol was applied as
described [12], from which systemic distribution of
[18F]AF78 in the healthy rat was obtained. Homogeneous
and clear radiotracer uptake throughout the left ventricular
wall was observed. Though traces of delineation of the right
ventricular wall were seen in transverse and coronal images,
the limited discernible uptake might be due to the partial-
volume effect caused by the thinness of the right ventricular
wall (Fig. 5c, no pretreatment). Pretreatment with NET
blocker PhB (50 mg/kg) intravenously via tail vein 10 min
before the radiotracer injection significantly reduced the
radiotracer uptake in the left ventricular myocardium
counting more than 64 % decrease (Fig. 5c, NET
blockade). Notably, [18F]AF78 showed high cardiac uptake
compared to the low uptake in the adjacent organs such as
blood, liver and lungs. Low bone uptake during the imaging
period suggests stability at the early stage after radiotracer
administration.
Discussion
Multiple fluorine-18-labelled PET radiotracers targeting
NET have been previously described. Among these
reported tracers, [18F]LMI1195 and [18F]4F-MHPG/3F-
PHPG have confirmed safety and tolerance in human
subjects along with favourable biodistribution and kinetics
suitable for NET imaging. From the chemical structural
point of view, the former one possesses a benzylguanidine
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Fig. 4 Results of the competitive cell uptake assay. a Dose-response curves of [131I]MIBG uptake in SK-N-SH cells in the
presence of increasing concentrations of nonradioactive compounds; results are expressed as percent of [131I]MIBG uptake.
Norepinephrine (violet), 4F-MHPG (green), cold reference AF51 (blue) and cold reference AF78 (red). IC50 values of
norepinephrine, 4F-MHPG and cold reference AF78 (n = 3) are 1.38 ± 0.25, 6.80 ± 0.73 and 2.57 ± 1.37 μM, respectively. b
Dose-response curves of [18F]AF78 uptake in SK-N-SH cells in the presence of increasing concentrations of nonradioactive
compounds; results are expressed as percent of [18F]AF78 uptake. Norepinephrine (black), 4F-MHPG (blue) and cold reference
AF78 (red) inhibited the uptake of [18F]AF78 at IC50 values of 0.60 ± 0.27, 0.85 ± 0.63 and 2.68 ± 0.83 μM, respectively. c
Radiotracer uptake in the SK-N-SH cells in the absence and presence of NET inhibitor desipramine (DMI). [131I]MIBG (left, n = 3,
87 % inhibition compared to the control) and [18F]AF78 (right, n = 6 for control, n = 4 for DMI, 94 % inhibition compared to the
control) uptake with and without NET inhibitor DMI. ***p G 0.001.
core structure derived from [123I]MIBG, while the latter
ones possess phenethylguanidine core structure and show
slow cardiac uptake mechanism in rat models [15, 16].
However, multiple aspects of NET radiotracer develop-
ment have yet to be completely addressed. For example,
one crucial question in the fluorine-18-labelled tracer
design is where to introduce advantageously fluorine-18:
either through nucleophilic substitution of tosylate, triflate
or mesylate on an alkyl chain, such as in the case of
[18F]LMI1195; or direct nucleophilic substitution of
iodonium on the benzene ring, as illustrated by
[18F]MFBG or [18F]4F-MHPG/3F-PHPG [15]. Obviously,
the fluorination in the latter case is more challenging due
to the electron-rich benzene ring. Therefore, the strategy to
introduce fluorine as in the former case is chosen for the
currently reported radiotracers. As has been demonstrated
by the aforementioned results obtained from the compet-
itive cell uptake studies of [18F]AF78, the introduction of
3-fluoropropoxy substitution at the para-position is very
well tolerated. Similarly, the derivation of [18F]FPOIBG
from [123I]MIBG also confirmed the feasibility of this
strategy [27]. Unfortunately, the introduction of 3-
fluoropropoxyl group to the meta-position is not tolerated
by NET as we found with AF51. Nevertheless, a
[ 1 2 3 I ]MIBG ana logue meta - [ 1 8F ] f l uo rop ropy l -
benzylguanidine ([18F]mFPBG) reported last year showing
desipramine sensitive uptake-1-specific cardiac uptake in
rats demonstrated a controversial finding that should raise
our attention [28]. As suggested by the chemical structure of
[123I]MIBG, themeta-position might only tolerate substituents
up to a certain size not larger than iodine. [18F]LMI1195 with
bromine at meta-position demonstrated significantly higher
cardiac uptake ratio than [123I]MIBG [29], whereas the
corresponding iodine derivative [18F]FPOIBG showed lower
uptake in three cell line-based studies and in mice studies [27].
Similarly, the mere [18F]fluorine-derivative of MIBG
[18F]FIBG, though focusing on tumour imaging, failed to
represent high cardiac uptake over liver [30], which demon-
strated that a mere introduction of fluorine will influence the
in vivo character not as simple as it might appear. Moreover,
although an acceptable radiochemical yield could be reached
with direct benzene-ring nucleophilic fluorination, exempli-
fied by [18F]MFBG (two steps, 56 min, 31 %) [23], the low
radiolabelling yield of [18F]4F-MHPG (three steps, 150 min,
7 % and two steps, 90 min, 7 % after improvement) [16, 18]
would still hinder their potentiality in clinical application.
[18F]FPOIBG (two steps, 105 min, 5.2 %) with 3-
fluoropropoxy moiety did not give higher radiochemical yield
without radiolabelling procedure optimization [27], while the
radiochemical yield of [18F]LMI1195 was not reported,
neither in literature nor in patent, and is therefore difficult to
compare with. We presume that the data from [18F]LMI1195
should be comparable to ours because of a similar
radiolabelling principle. These results should be taken into
consideration in the development of other NET tracers with
related structures.
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Fig. 5 a Autoradiography of the left ventricular short axis slices from rats. [18F]AF78 demonstrated an even distribution
throughout the myocardium (control), which was greatly suppressed by pretreatment with phenoxybenzamine (PhB, 50 mg/kg
iv injection, NET blockade). b Tissue distribution ratios of [18F]AF78. The columns are the mean value of 2 rats. Data were
determined 10 min post-radiotracer injection. Y-axis represents the heart/tissue distribution ratio. Both the heart-to-blood ratio
and the heart-to-liver ratio decreased significantly after pretreatment with PhB (50 mg/kg iv injection, NET blockade). c Static
PET images of cardiac uptake of [18F]AF78 in healthy rats, with (NET blockade) or without (no pretreatment) pretreatment with
NET blocker PhB (50 mg/kg iv injection) 10 min before radiotracer injection. Homogeneous [18F]AF78 distribution throughout
the left ventricular wall can be seen, which can be reversed by pretreatment with PhB.
Furthermore, all of these radiotracers represent important
monoamine oxidase resistance for long-term stable neuronal
storage due to the guanidine moiety. Nevertheless, guanidine
is a complex structure during the radiofluorination proce-
dure, as any non-protected part of the moiety will interfere
with the necessary nucleophilic process. One solution that
has been used for the radiolabelling of [18F]4F-MHPG/3F-
PHPG is the tetrakis-Boc protection group [18], while others
chose a triazinanone structure to fully protect it as in the case
of [18F]MFBG [22, 23]. In our study, the triazinanone
structure that has been used to fully protect the guanidine
moiety has demonstrated its stability during the
radiolabelling procedure since it fully decomposed only
after the treatment in strong acidic conditions for a long
period of time. Such a protection strategy may be useful in
future synthetic efforts, where a guanidine moiety needs to
be introduced first but followed by harsh reaction conditions
that it still remains completely protected. Moreover, in
multiple-step radiolabelling procedures, the triazinanone
structure could also be used to allow for more diverse
radiotracer design and/or flexible labelling procedures.
Although nometabolism studies have been performed at the
current stage, it can be inferred that [18F]AF78 is also stable
against monoamine oxidase with its phenethylguanidine
structure. Additionally, due to the alkylation at the para-
hydroxyl group, the potential metabolite from sulphate
conjugation, as in the case of [18F]4F-MHPG, will be
prevented [16]. This may lead to longer radiotracer retention.
A long-term dynamic imaging using [18F]AF78 in other animal
species is currently in progress, not only to evaluate the uptake
and clearance in organs of interest but also to assess the
stability of 3-fluoropropoxy substituent, because slightly
increased bone activity in later frames of [18F]LMI1195 PET
studies in rats could be observed, which suggested the presence
of free fluorine-18 [12]. Besides, following the current
successful strategy of derivation, further effort on replacing
the substitutions on the benzene-ring will also be included in
future plans in the hope of gaining radiotracers with improved
in vivo characteristics, such as longer cardiac retention time or
better background contrast.
Competitive cell uptake studies revealed a NET-specific
radiotracer uptake mechanism as compared with [123I]MIBG
and norepinephrine, which was sensitive to the uptake-1
selective blocker desipramine. Different from humans, there
is also an extra-neuronal uptake mechanism, i.e., uptake-2,
that exists in rat hearts. Therefore, in both ex vivo and in vivo
studies, the cardiac uptake of [18F]AF78 could only be
suppressed by non-selective norepinephrine/radiotracer up-
take blocker phenoxybenzamine [31], which demonstrated
an extra-neuronal dominant uptake of the radiotracer.
Obviously, a species difference plays an important role in
such a case, because both [123I]MIBG and [18F]LMI1195
have also shown significant uptake-2 mechanism preference
in small rodents [12]. Larger animal studies are at the
moment in progress for a deeper understanding of its in vivo
characteristics, especially regarding the uptake kinetics, in
order to gain insight into the potential applications in
humans. Species differences between small rodents and
other animal species, especially humans, should be taken
into consideration because of the significant variations in
systemic and local norepinephrine metabolism.
Cardiac imaging and blocking protocol of the current
study are based on the experience investigating
[18F]LMI1195 [12]. Indeed, 10-min of PET imaging is too
short to measure delayed kinetics of radiotracer, but it is
enough to reveal the initial radiotracer uptake and clearance
based on our experience from [18F]LMI1195 studies.
Besides, the main purpose of the current study is a proof
of concept to design new series of NET targeting radio-
tracers. By showing the specific cardiac uptake in the rat
hearts with good H/B and H/L ratios, we successfully
demonstrated the feasibility of the design strategy presented
above.
The results of tissue biodistribution studies of [18F]AF78,
namely H/B 12.54 ± 0.53 and H/L 6.14 ± 0.35, obtained
10 min after radiotracer administration, are comparable to
[123I]MIBG (H/B 11.91 ± 1.60, H/L 2.42 ± 0.41) and
[18F]LMI1195 (H/B 15.56 ± 3.61, H/L 6.21 ± 1.68) [29].
Thereby, the favourable myocardium uptake of [18F]AF78,
with low background activity, facilitates the possibility of
evaluating the inferior wall activity of the heart. Again,
evaluation in different animal species, especially NET-
mediated radiotracer uptake-1 dominant ones, such as
rabbits, is obviously needed for further comparison with
currently reported radiotracers.
Indeed, there are a few PET tracers targeting the NET that
have been investigated both in different animal models
(mainly rats and rabbits) and in human subjects (either
healthy volunteers or patients with cardiac diseases), as has
been discussed in full detail in several reviews [1, 3, 32].
Carbon-11-labelled tracer hydroxyephedrine ([11C]HED)
along with [18F]LMI1195 and [18F]4F-MHPG/3F-PHPG
have drawn most attention. The former [11C]HED has been
investigated intensively in Japan involving a large number
and varieties of patients to confirm the feasibility of
[11C]HED in quantifying regional sympathetic denervation
[33], estimating myocardial blood flow [34] and to detect
cardiac denervation due to Parkinson’s disease [35]. A
couple of clinical trials have also been performed in Canada
and in the USA. For example, the prospective PAREPET
trial enrolled 204 subjects with ischemic cardiomyopathy
demonstrated a strong association between the volume of
denervated myocardium assessed by [11C]HED and cardiac
events [36]. The latter fluorine-18-labelled new generation
NET tracers, exemplified by [18F]LMI1195 and [18F]4F-
MHPG/3F-PHPG, have been in clinical phase 1 trial with
proved safety and tolerance in humans, and reported within
the last decade. Consequently, not so many clinical trials on
human subjects have been performed in comparison to
[11C]HED. However, fluorine-18-labelled radiotracers might
outperform current SPECT-based [123I]MIBG or carbon-11-
labelled radiotracers in the long run, as the several
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advantages emphasized in the introduction section, espe-
cially due to the longer physical half-life (110 min of
fluorine-18 over 20 min of carbon-11), and better spatial and
temporal resolution. [18F]LMI1195 is derived directly from
[123I]MIBG and shares similar in vitro [14] and in vivo [13]
characteristics, including selective uptake-1 mechanism and
stable storage in presynaptic storage vesicles. Differently,
[11C]HED represents continuous leaking and reuptake
equilibrium at the nerve terminal. Furthermore, clinical
phase 1 trial of [18F]LMI1195 has demonstrated the
tolerance and safety in humans but with a higher effective
dose than [123I]MIBG [17]. Similar to the application of
[123I]MIBG in endocrine tumours, it shows high and specific
accumulation in pheochromocytomas, which represented
another potential clinical application [37]. Of note, in a
recently published comparison of [18F]LMI1195 with
[11C]HED, preliminary data suggests a comparable estimates
of cardiac sympathetic innervation but offers more
favourable kinetics for early cardiac imaging [38], which
shows the way to further clinical phase 2 trial in predicting
arrhythmic events (NCT03493516). In addition to specific
cardiac uptake with high selectivity and long period
retention as defined by the authors as “irreversible neuronal
retention” [18], [18F]4F-MHPG/3F-PHPG have drawn much
attention due to their slow uptake kinetics compared to
[123I]MIBG and [11C]HED, which is useful in measuring
regional cardiac sympathetic nerve density quantitatively
using Patlak graphical analysis [19]. One interesting point is
the different metabolism of [18F]4F-MHPG and [18F]3F-
PHPG in human studies [19]. As a pair of isomers, it
revealed in vivo structure-activity relationships as [18F]4F-
MHPG metabolized more quickly to form a sulphate at
meta-hydroxyl position, whereas the metabolites of [18F]3F-
PHPG remain unknown, but neither as sulphate nor as
glucoside. From chemical structural point of view, this could
be used to explain the even slower neuronal accumulation of
[18F]3F-PHPG (10 min of [18F]4F-MHPG vs. 30 min of
[18F]3F-PHPG) and higher H/L ratio of [18F]4F-MHPG due
to its faster liver clearance (2.4 of [18F]4F-MHPG vs. 1.2 of
[18F]3F-PHPG). Whether in vivo metabolism is as important
as claimed remains controversial, but [18F]AF78 may
provide an alternative by preventing the metabolism caused
by a hydroxy group while potentially retaining the similar
in vivo character with proved easy radiolabelling procedure
and higher radiochemical yield. Although more detailed
radiotracer kinetics of [18F]AF78 need to be further
determined, the current study can be considered as the first
step of adapting certain advantages from both [18F]LMI1195
and [18F]4F-MHPG/3F-PHPG pair.
Conclusions
A novel PET radiotracer, [18F]AF78, targeting NET with a
phenethylguanidine structure has been designed and evalu-
ated. The compound demonstrated high affinity and specific
cardiac uptake. Additionally, the para-position substitution
3-fluoropropoxyl group provided an alternative way to
introduce fluorine-18 with good radiolabelling yield and
radiochemical purity. The introduction of a fully protected
guanidine markedly improved stability of the precursor
during the synthesis and radiolabelling procedure.
Favourable H/B and H/L ratios along with NET-sensitive
uptake indicate that [18F]AF78 might allow for highly
specific sympathetic nervous system imaging in human
hearts, additionally with the potential of quantitative regional
sympathetic nerve density measurement independent from
blood flow. Furthermore, its potential application in the
theranostics of neuroendocrine tumours can also be consid-
ered because of the successful clinical application of [123I]/
[131I]MIBG.
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